Patents by Inventor John F. Palma

John F. Palma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230270769
    Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide.
    Type: Application
    Filed: December 28, 2022
    Publication date: August 31, 2023
    Inventors: Tatiana I. Vener, Carlo C. Derecho, John F. Palma, Mical Raponi
  • Patent number: 11559540
    Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: January 24, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Tatiana I. Vener, Carlo C. Derecho, John F. Palma, Mical Raponi
  • Publication number: 20210002719
    Abstract: The invention is a method of predicting response to therapy in a colorectal cancer patient, the method comprising measuring tumor genetic heterogeneity via analysis of circulating tumor DNA from a patient's sample.
    Type: Application
    Filed: February 11, 2019
    Publication date: January 7, 2021
    Inventors: Fergal Casey, John J. Lee, John F. Palma, Stephanie J. Yaung
  • Publication number: 20160138103
    Abstract: Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility.
    Type: Application
    Filed: May 13, 2015
    Publication date: May 19, 2016
    Inventors: John F. Palma, John W. Backus, Yixin Wang, Jack X. Yu, Yi Zhang, Tatiana Vener, Carlo Derechio, Dong U. Lee
  • Publication number: 20160095874
    Abstract: The disclosed method rapidly identifies with desired accuracy AML patients, including elderly AML patients, likely to respond to treatment with a combination of a farnesyltransferase inhibitor and one or more of etoposide, teniposide, tamoxifen, sorafenib, paclitaxel, temozolomide, topotecan, trastuzumab and cisplatinum. In an embodiment, the improvements include the use of whole blood rather than the customary bone marrow sample, thus making the assay more accurate, rapid, less intrusive, less expensive as well as less painful. The method includes evaluation of a two-gene expression ratio (RASGRP1:APTX), which with a corresponding threshold, provides sufficient accuracy for predicting the response to the combination treatment. In the preferred embodiment the combination treatment combines tipifarnib (R115777, ZARNESTRA®) with etoposide.
    Type: Application
    Filed: January 25, 2013
    Publication date: April 7, 2016
    Inventors: Tatiana I. Vener, Carlo C. Derecho, John F. Palma, Mical Raponi
  • Publication number: 20110275079
    Abstract: Methods are disclosed for the identification of gene sets that are differentially expressed in PBMCs of patients diagnosed with a pre-diabetic disease state and overt type II diabetes. 3 gene and 10 gene signatures are shown to accurately predict a diabetic disease state in a patient. The application also described kits for the rapid diagnosis of diabetic disease states in patients at a point of care facility.
    Type: Application
    Filed: November 13, 2008
    Publication date: November 10, 2011
    Inventors: John F. Palma, John W. Backus, Yixin Wang, Jack X. Yu, Yi Zhang, Tatiana Vener, Carlo Derecho, Dong U. Lee
  • Publication number: 20110166030
    Abstract: A method for predicting with high specificity from RTPCR detected markers if a patent is likely to respond to docetaxel treatment is disclosed. RTPCR detects the presence of absence of certain mutations due to fusion events. Together, with other protein markers, additional stratification is possible to identify patents suited for docetaxel therapy as opposed to for alternative treatments.
    Type: Application
    Filed: September 28, 2010
    Publication date: July 7, 2011
    Inventors: Yixin Wang, Yuqiu Jiang, John F. Palma
  • Publication number: 20110009288
    Abstract: An assay for identifying early stage malignant melanocyte in biopsy tissues is provided by determining whether differential expression of a particular gene indicative of melanoma exceed a cut-off value.
    Type: Application
    Filed: July 8, 2010
    Publication date: January 13, 2011
    Inventors: Dmitri TALANTOV, John F. Palma, Tatiana Vener, Tim Jatkoe, Haiying Wang, Yixin Wang
  • Publication number: 20100109050
    Abstract: A field effect transistor (FET) having at least two independently biased gates can provide uniform electric field in the channel region of the FET. The same AC voltage may be applied to each gate for modulating the FET. One of the gates is positioned closer to the channel region than the other gate. Such a FET allows tailoring the electric field in the channel region of the FET so that it is substantially uniform. The FET exhibits desirable performance characteristics, including having a constant transconductance.
    Type: Application
    Filed: November 4, 2009
    Publication date: May 6, 2010
    Applicant: University of Massachusetts
    Inventors: Samson Mil'shtein, John F. Palma
  • Patent number: 7629627
    Abstract: A field effect transistor (FET) having at least two independently biased gates can provide uniform electric field in the channel region of the FET. The same AC voltage may be applied to each gate for modulating the FET. One of the gates is positioned closer to the channel region than the other gate. Such a FET allows tailoring the electric field in the channel region of the FET so that it is substantially uniform. The FET exhibits desirable performance characteristics, including having a constant transconductance.
    Type: Grant
    Filed: April 18, 2006
    Date of Patent: December 8, 2009
    Assignee: University of Massachusetts
    Inventors: Samson Mil'shtein, John F. Palma
  • Patent number: 7491533
    Abstract: The present invention provides polynucleotides encoding potassium channels as well as methods of using the potassium channels to treat and diagnose diabetes and a predisposition for diabetes.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: February 17, 2009
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, John F. Palma, Anthony C. Schweitzer, John E. Blume
  • Publication number: 20080318312
    Abstract: The present invention provides a pancreatic islet transcription factor and methods of treating and diagnosing diabetes.
    Type: Application
    Filed: June 27, 2008
    Publication date: December 25, 2008
    Applicant: METABOLEX, INC.
    Inventors: Jeffrey D. Johnson, John F. Palma, Anthony C. Schweitzer, John E. Blume
  • Patent number: 7405289
    Abstract: The present invention provides a pancreatic islet transcription factor and methods of treating and diagnosing diabetes.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: July 29, 2008
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, John F. Palma, Anthony C. Schweitzer, John E. Blume
  • Patent number: 7374927
    Abstract: The invention provides arrays for analysis of compromised nucleic acid samples, for example, nucleic acids obtained from formalin fixed paraffin embedded samples and methods to analyzed these compromised samples. Arrays are disclosed in which the probe selection region used to select probes for the array is the 300 bases of the target MRNA that are immediately upstream of the start of the poly(A) tail of the mRNA. The probes selected for the array are more biased toward the 3? end of the mRNA than other arrays that are currently available.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: May 20, 2008
    Assignee: Affymetrix, Inc.
    Inventors: John F. Palma, Eric B. Schell, Alan J. Williams
  • Patent number: 7294698
    Abstract: The invention relates to methods and reagents for diagnosing and treating diabetes.
    Type: Grant
    Filed: November 1, 2006
    Date of Patent: November 13, 2007
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D Johnson, John E. Blume, John F. Palma, Yun-Ping Zhou
  • Patent number: 7144985
    Abstract: The invention relates to methods of determining islet cell activity by detecting the level of Archipelin or a fragment thereof and comparing the level to a baseline level or range associated with a known islet cell activity. Such methods are useful in diagnosing and studying the development of diabetes.
    Type: Grant
    Filed: December 2, 2002
    Date of Patent: December 5, 2006
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, John E. Blume, John F. Palma, Yun-Ping Zhou
  • Patent number: 7053180
    Abstract: The present invention provides polynucleotides encoding potassium channels as well as methods of using the potassium channels to treat and diagnose diabetes and a predisposition for diabetes.
    Type: Grant
    Filed: June 10, 2003
    Date of Patent: May 30, 2006
    Assignee: Metabolex, Inc.
    Inventors: Jeffrey D. Johnson, John F. Palma, Anthony C. Schweitzer, John E. Blume
  • Publication number: 20040072216
    Abstract: The present invention provides polynucleotides encoding potassium channels as well as methods of using the potassium channels to treat and diagnose diabetes and a predisposition for diabetes.
    Type: Application
    Filed: June 10, 2003
    Publication date: April 15, 2004
    Applicant: METABOLEX, INC.
    Inventors: Jeffrey D. Johnson, John F. Palma, Anthony C. Schweitzer, John E. Blume
  • Publication number: 20040029151
    Abstract: Many genes are affected in prostate cancers which have not been previously identified. This includes genes that have been up-regulated or down-regulated. Monitoring the expression levels of these genes is useful to identify the existence of prostate cancer. Also, monitoring the expression levels of these genes is useful to predict the effectiveness of treatment, outcome, use of therapeutics, and screening drugs useful for the treatment of prostate cancer.
    Type: Application
    Filed: April 9, 2003
    Publication date: February 12, 2004
    Applicant: Affymetrix, INC.
    Inventors: Mamatha Mahadevappa, Zhaomei Zhang, Janet A. Warrington, John F. Palma, Mitchell C. Caldwell, Zuxiong Chen, Zhenbin Fan, John E. McNeal, Rosalie Nolley, Thomas A. Stamey
  • Publication number: 20030202976
    Abstract: The invention relates to methods and reagents for diagnosing and treating diabetes.
    Type: Application
    Filed: December 2, 2002
    Publication date: October 30, 2003
    Applicant: METABOLEX, INC.
    Inventors: Jeffrey D. Johnson, John E. Blume, John F. Palma, Yun-Ping Zhou